Pamiparib, a potent and selective PARP-1/2 inhibitor independently developed by BeiGene, fills the treatment gap for patients who have received second-line or later-line chemotherapy.
Authentic
Guarantee
Fast Delivery
Privacy Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



